Skip to main content
Grand Pharmaceutical Group Limited logo

Grand Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 512 ISIN · BMG210A71016 LEI · 8945001XW4FS15S8Z778 HKEX Manufacturing
Open in API
Filings indexed 1,169 across all filing types
Latest filing 2025-08-01 Regulatory Filings
Country BM Bermuda
Listing HKEX 512

About Grand Pharmaceutical Group Limited

http://www.grandpharma.cn

Grand Pharmaceutical Group Limited is an international, technology-driven pharmaceutical enterprise specializing in the research, development, manufacture, and sale of innovative healthcare solutions. The company's strategic focus encompasses three primary areas: pharmaceutical technology, nuclear medicine for anti-tumor diagnosis and treatment, and cerebro-cardiovascular precision intervention. Key product lines include anti-tumor and cardiovascular emergency pharmaceutical products, as well as intervention medical devices. The organization maintains a strong commitment to R&D, actively developing next-generation therapies, such as mRNA drugs designed to combat tumors and infections. Additionally, the company provides a range of bio-health products, including amino acid and taurine series.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025
Regulatory Filings Classification · 1% confidence The document is clearly the HKEX form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules. It details movements in authorised and issued share capital, share options, convertibles, and includes confirmations under Listing Rules. This is a routine periodic regulatory return to the exchange, not an earnings release, management report, proxy materials, or a one‐off capital change announcement. It therefore falls into the fallback category “Regulatory Filings” (RNS).
2025-08-01 English
VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP
Major Shareholding Notification Classification · 1% confidence The document is a voluntary announcement by Grand Pharmaceutical Group concerning an internal restructuring of shareholdings: Outwit Investments (the controlling shareholder) acquires additional shares, increasing its stake from 47.09% to 53.42%, which crosses the 2% threshold and invokes the Hong Kong Code on Takeovers and Mergers. There is no issuance of new shares, repurchase, dividend, or AGM materials. This is a clear notification of a material change in major shareholding levels, fitting the Major Shareholding Notification category.
2025-07-28 English
VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE III CLINICAL TRIAL OBTAINS IMPLIED APPROVAL FROM THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed with the Hong Kong Exchange announcing R&D progress (implied approval for TLX591 Phase III trial), pipeline updates, and manufacturing base details. It is a substantive press‐style release, not a full financial report, earnings release, or investor slide deck, and does not involve dividends, share issues, legal proceedings, or management changes. It therefore falls into the fallback category of general regulatory announcements (RNS).
2025-07-22 English
SUPPLEMENTAL ANNOUNCEMENT TO CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement providing supplemental information on continuing connected transactions (a Business Collaboration Agreement) including details of R&D projects, pricing terms, caps, internal controls and shareholding updates. It is not a full report (10-K, IR, IP, etc.), nor a notice of dividend, director change, earnings release or M&A transaction. It is a regulatory disclosure announcement falling into the general Regulatory Filings (RNS) category.
2025-07-17 English
VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST NASAL SPRAY PRODUCT OF THE GROUP FOR THE TREATMENT OF DRY EYE DISEASE, OC-01, ACHIEVES THE FIRST BATCH OF COMMERCIAL PRESCRIPTIONS AFTER ITS OFFICIAL APP
Regulatory Filings Classification · 1% confidence The document is a voluntary business update announcing the first commercial prescriptions of a new nasal spray product and detailing R&D progress. It contains no financial statements, earnings metrics, board changes, dividends, or regulatory/legal notices. It is not a formal report (Annual, Interim, Audit) but a corporate announcement. It does not fit specialized categories like M&A, dividends, management changes, etc. As a general corporate filing announcing business developments on HKEx, it falls under the fallback category “Regulatory Filings (RNS).”
2025-07-17 English
VOLUNTARY ANNOUNCEMENT: A NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE INJECTION IS OFFICIALLY APPROVED BY THE FDA AHEAD OF SCHEDULE
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement made to the Hong Kong Exchange disclosing FDA approval of a new product indication. It does not present financial results (so it is not an earnings release, annual or interim report), nor does it announce board changes, capital actions, dividends, or M&A. It is narrative, not a slide deck, and no report is attached. Therefore, it falls under general regulatory announcements/fallback category.
2025-07-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.